Physician profile
Michael Golden
NPI 1609872571
$2,050.93
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,659 · 2020: $392.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $466.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $168.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $145.48 | 2019 | |
| Astellas Pharma US INC | $114.13 | 2019-2020 | |
| Abbvie INC. | $104.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $86.97 | 2019-2020 | |
| Antares Pharma, INC. | $86.76 | 2019-2020 | |
| Horizon Therapeutics Plc | $86.21 | 2019 | |
| Amgen INC. | $71.93 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $57.73 | 2019-2020 | |
| Radius Health, INC. | $57.30 | 2019-2020 | |
| Sanofi Pasteur INC. | $51.79 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $44.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $37.25 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31.15 | 2019 | |
| Genentech USA, INC. | $30.71 | 2019-2020 | |
| Therapeuticsmd, INC. | $23.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.09 | 2020 | |
| Novo Nordisk INC | $19.80 | 2019 | |
| Valeritas, INC. | $19.74 | 2019 | |
| Sobi, INC | $17.59 | 2019 | |
| Seqirus USA INC | $17.14 | 2019 | |
| Shire North American Group INC | $15.83 | 2019 | |
| Merck Sharp & Dohme LLC | $15.72 | 2019 | |
| Lilly USA, LLC | $15.44 | 2019 | |
| Ibsa Pharma INC. | $14.92 | 2019 | |
| Millicent US INC | $14.22 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.